Conference Day Two
Thursday 27th February 2025
8:00 am Check in & Morning Coffee
8:50 am Chairperson’s Opening Remarks
Understanding Radiobiological Mechanisms of Killing & Immune Stimulation to Match Optimal Radiopharmaceutical Targets
9:00 am Understanding the Effects of Radiopharmaceuticals on Immune-Mediated Responses & Isotope Comparison on Anti-Tumor Immunity
Synopsis
- Comparing the immunologic effects of clinically-relevant radiopharmaceutical isotopes on anti-tumor immunity
- Exploring poorly immunogenic tumors with intrinsic resistance to ICIs, combination with high LET, short-range alpha-emitters may prime adaptive CD8+ T cell recognition
- Outlining acquired resistance to ICIs, low doses of low LET, longer range beta-emitting RPT may provide tumor inflammation and tumor cell susceptibility needed to renew clonal expansion of existing tumor-specific CD8+ T cells and generate immunologic memory
9:30 am Roundtables: Interrogating Radiopharmaceutical Mechanisms of Resistance to Build Strategies for Overcoming Them
Synopsis
- Identifying molecular drivers of resistance such as alterations in DNA repair pathways, tumor microenvironment changes, and efflux transporters
- Understanding how adaptive responses, such as changes in target expression or immune evasion, can lead to reduced effectiveness of radiopharmaceuticals
- Explore innovative strategies to overcome resistance
10:00 am Exploring CAR-T & Radiopharmaceutical Combinations in Solid Tumors for Enhanced Efficacy
Synopsis
- Appreciating that CAR T cells have shown limited effectiveness against solid tumors for various reasons
- Outlining the increasing evidence of the immunostimulatory effects of radiopharmaceutical therapy,
- Addressing some of the challenges faced by CAR T cell therapy especially in the metastatic setting
10:30 am Morning Coffee Break
Rational Drug Design for Radiopharmaceuticals: Cutting-Edge Targeting Moieties for Optimal Drug Properties
11:30 am Optimizing Radiopharmaceutical Drug Design: Evaluating Approved Therapies & Exploring Novel Chelator & Linker Approaches
Synopsis
- Exploring the advantages and disadvantages of target vehicles (such as small molecules, peptides, and antibodies)
- Outlining lessons learned from the current approved radiopharmaceuticals.
- Selection of radionuclides and chelating agents for the development of radiopharmaceuticals for theranostics (imaging and therapy)
12:00 pm Bicycle Radionuclide Conjugates Targeting Novel Antigens for Radioisotope Delivery into Solid Tumors
Synopsis
- Outlining the proprietary Bicycle® screening platform can identify novel peptidic binders to complex targets that lack pre-existing peptide-based ligands and then convert these into high affinity and selective Bicycle® molecules
- Revealing development of Bicycle radionuclide conjugates (BRCs) targeting MT1-MMP and EphA2
- Sharing preclinical data from proteins that are widely expressed in a variety of cancers with high unmet medical need
12:30 pm Target Selection & Clinical Performance Metrics of Beta Emitting Isotopes
Synopsis
- Understanding optimal targets for varying isotopes
- Exploring early drug design choices for clinical performance
1:00 pm Lunch Break & Networking
Rational Drug Design for Radiopharmaceuticals – Chelator & Linker Developments
2:00 pm Advancing Chelator Technologies for Enhanced Radiopharmaceutical Development
Synopsis
- Promoting altered drug properties
- Outlining chelators of choice
- Improving the pharmacokinetics and biodistribution of radiopharmaceuticals
2:30 pm From Bench to Bedside 2025: Bridging the Gap using Key Considerations for First-in-Human Trials
Synopsis
- Discussing challenges and considerations in translating radiopharmaceutical research into First-in-Human (FIH) clinical trials
- Understanding Regulatory Landscape and IND Considerations